[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.166.74.94. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Letters
April 28, 2004

Combined Antiretroviral Therapy During Pregnancy and Risk of Congenital Malformations—Reply

Author Affiliations
 

Letters Section Editor: Stephen J. Lurie, MD, PhD, Senior Editor.

JAMA. 2004;291(16):1961-1962. doi:10.1001/jama.291.16.1962

In Reply: In response to Dr Frieden and colleagues, we point out that the prevalences of congenital anomalies in the group treated with CART and the control group were not significantly different from one another (5.6% vs 1.7%, P = .09), whereas a significant difference was found in the prevalence of hemangiomas (4.2% vs 0.3%, P = .02). We selected a contemporary control group exposed to nonteratogenic drugs because, considering the importance of this therapy during pregnancy, a contemporary HIV-positive group not exposed to retroviral drugs was not available. Our 3 cases of hemangioma were found in 3 male infants, of whom only 1 was born prematurely (gestational age, 36 weeks). The case from among the control group was a female infant born at term of pregnancy.

First Page Preview View Large
First page PDF preview
First page PDF preview
×